BioLineRx Ltd. (BLRX) Given a $1.00 Price Target at Maxim Group
Several other brokerages have also commented on BLRX. Roth Capital reaffirmed a buy rating and issued a $7.00 price objective on shares of BioLineRx in a research report on Monday, September 26th. Zacks Investment Research lowered shares of BioLineRx from a buy rating to a hold rating in a research report on Tuesday, October 11th. Finally, S&P Equity Research lowered their price objective on shares of BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $2.68.
Shares of BioLineRx (NASDAQ:BLRX) traded down 2.73% on Tuesday, hitting $1.07. 26,717 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $1.07 and its 200 day moving average is $0.94. The firm’s market cap is $60.37 million. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.63.
BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, November 22nd. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. On average, equities analysts predict that BioLineRx will post ($0.26) earnings per share for the current year.
A number of institutional investors have recently modified their holdings of the stock. KCG Holdings Inc. boosted its position in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares in the last quarter. Morgan Stanley boosted its position in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares in the last quarter. Finally, Senvest Management LLC boosted its position in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares in the last quarter. 14.35% of the stock is owned by institutional investors.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.